Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, ...

Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other ...

Treatments for uveitic macular edema, including systemic and local options, were among the topics debated at the Congress on Controversies in Ophthalmology.

Latanoprostene bunod 0.024% significantly reduced IOP across patient groups and appeared well regarded among physicians and ...

In July 2025, CSL Behring conducted a study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after ...

Nicox SA, an international ophthalmology company, announced the signing of a major new agreement concerning NCX 470 with Kowa Company, Ltd., a Japanese company with a global pharmaceutical business ...

A new study published in the Nature Scientific Reports showed that compared to kidney recipients who got preemptive transplants, individuals who experienced dialysis prior to transplantation are ...

Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma ...

A review reveals dangerous vitamin deficiencies post-bariatric surgery, highlighting the need for improved follow-up to ...

Zenyaku Kogyo Co. Ltd. has identified myosin light chain kinase family member 4 (MYLK4; SGK085) inhibitors reported to be useful for the treatment of arteriosclerosis, inflammatory bowel disease, ...